Navigation Links
Multidisciplinary meeting on urological cancers aims to benefit cancer patients
Date:11/19/2009

Arnhem, November 2009 -- Experts agree that the urological cancer patient will benefit greatly if the delivered treatment is the result of a combined effort. Collaboration of experts from various fields is, therefore, necessary to take cancer-related research and medical practice to the next level. The 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC) Embracing Excellence in Prostate, Bladder and Kidney Cancer - which is to take place on 27-29 November 2009 in Barcelona (ES), brings together urologists, radiologists and medical oncologists by enabling them to share their knowledge and experience. The meeting is organised by the European Association of Urology (EAU), the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology and Oncology (ESTRO) and was first held two years ago.

With the objective to facilitate multidisciplinary approaches that aim to optimise diagnostic, therapeutic and preventional interventions directed towards malignant disorders in the urogenital tract, the 2nd EMUC Meeting will feature presentations on the latest research from selected, translational and clinical abstracts, as well as related scientific and educational sessions.

"Meetings such as these are of great significance in promoting further scientific collaboration, not just on an international level, but even more so between the various experts working in the challenging and fast evolving fields of prostate, bladder and renal cell cancer", says Prof. Per-Anders Abrahamsson from Malm (SE), member of the EMUC Organising Steering Committee on behalf of the EAU.

Screening for prostate cancer, a much debated subject with far-reaching consequences, is one of the interesting issues on the meeting's agenda. According to Prof. Jos Baselga, Barcelona (ES), member of the EMUC Organising Steering Committee on behalf of the ESMO: "New compounds for the treatments of castrate-resistant prostate cancer and advanced renal cell carcinoma will be discussed. Furthermore, subjects such as urine markers in the screening of bladder cancer and new systemic treatment modalities in advanced bladder cancer are highlighted in State-of-the-art lectures and debates during the meeting".

The meeting enables experts to present the most recent advances in prostate, bladder and renal cell cancer and spans the entire field; from bench research to clinical applications which should be of interest to both clinicians and basic scientists. The future of European (and worldwide) urological cancer research will largely depend on advances in these fields.

"The involvement of world experts in their fields, the broad spectrum of topics discussed including biology, prevention, diagnosis, therapy and quality of life issues should guarantee comprehensive coverage", says Prof. Michael Baumann, Dresden (DE), member of the EMUC Organising Steering Committee on behalf of the ESTRO.

A multidisciplinary approach in urooncological patient care will eventually become an essential part of routine health care. For that reason, collaboration between academia, health care providers in general, but especially among urologists, radiation oncologists and medical oncologists will be the future.

Barcelona with its many cultural and culinary wonders will be an entertaining and interesting backdrop for this meeting.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
2. SAGE launching new sports medicine journal in 2009: Sports Health: A Multidisciplinary Approach
3. APTAs Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change
4. Elsevier Launches SciVal Spotlight: New Tool Provides Multidisciplinary View of Research Performance
5. ECCO 15 -- ESMO 34 multidisciplinary cancer congress
6. Media registration for ECCO 15 -- ESMO 34 multidisciplinary cancer congress
7. Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress
8. Mastery of Myeloma Continuing Education Training Program for the Multidisciplinary Care Team Set for Western Region
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology: